Allworth Financial LP United Therapeutics Corp Transaction History

Allworth Financial LP

  • $16.1 Billion
  • Q3 2024

A detailed history of Allworth Financial LP transactions in United Therapeutics Corp stock. As of the latest transaction made, Allworth Financial LP holds 114 shares of UTHR stock, worth $41,295. This represents 0.0% of its overall portfolio holdings.

Number of Shares
114
Previous 147 22.45%
Holding current value
$41,295
Previous $46,000 13.04%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024
SELL
$311.04 - $363.55 $10,264 - $11,997
-33 Reduced 22.45%
114 $40,000
Q2 2024

Jul 23, 2024
BUY
$228.26 - $319.04 $8,902 - $12,442
39 Added 36.11%
147 $46,000
Q1 2024

Apr 25, 2024
BUY
$210.76 - $249.51 $4,425 - $5,239
21 Added 24.14%
108 $24,000
Q4 2023

Jan 24, 2024
BUY
$214.88 - $256.94 $429 - $513
2 Added 2.35%
87 $19,000
Q3 2023

Oct 31, 2023
BUY
$211.82 - $248.24 $635 - $744
3 Added 3.66%
85 $19,000
Q2 2023

Jul 18, 2023
BUY
$205.19 - $232.99 $14,568 - $16,542
71 Added 645.45%
82 $18,000
Q1 2023

Apr 18, 2023
BUY
$212.99 - $276.17 $2,129 - $2,761
10 Added 1000.0%
11 $2,000
Q4 2022

Jan 13, 2023
SELL
$205.95 - $280.43 $823 - $1,121
-4 Reduced 80.0%
1 $0
Q3 2022

Oct 18, 2022
BUY
$203.3 - $244.17 $813 - $976
4 Added 400.0%
5 $1,000
Q1 2022

Apr 22, 2022
SELL
$166.16 - $213.96 $7,144 - $9,200
-43 Reduced 97.73%
1 $0
Q4 2021

Jan 21, 2022
BUY
$184.32 - $216.08 $8,110 - $9,507
44 New
44 $10,000
Q2 2020

Jul 24, 2020
SELL
$92.74 - $125.82 $4,637 - $6,291
-50 Closed
0 $0
Q2 2017

Aug 07, 2017
BUY
N/A
50
50 $6,000

Others Institutions Holding UTHR

# of Institutions
672
Shares Held
42.4M
Call Options Held
194K
Put Options Held
295K
View Full List

About UNITED THERAPEUTICS Corp

UTHR Quotes by TradingView
  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.5B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email